most doubtfully, the 150k sales order on 0.22 seems that the price mover want to get out from this stock on the fair profit basis.Let us wait and see. Do not trade on this stock, let him trap himself.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%